Jessie P. Gu

Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy.

P. Giral, E. Bruckert, S. Dejager, 2008, Pharmacogenomics.

Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi)

R. Sarangapani, Jessie Gu, A. Noè, 2010, Journal of clinical pharmacology.

A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

A. Zelenetz, I. Flinn, T. Kipps, 2013 .

A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01).

Michael Thomas, Melissa L. Johnson, K. Yoh, 2021 .

Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL).

J. Byrd, J. Leonard, I. Flinn, 2013 .

O2-1 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study*

Toshio Shimizu, R. Heist, Melissa L. Johnson, 2021, Annals of Oncology.

P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC: Topic: Miscellaneous

Keunchil Park, R. Dziadziuszko, Dong-Wan Kim, 2017 .

Drug‐Drug Interaction Studies to Evaluate the Effect of Inhibition of UGT1A1 and CYP3A4 and Induction of CYP3A4 on the Pharmacokinetics of Tropifexor in Healthy Subjects

R. Woessner, W. Prince, Jessie Gu, 2022, Clinical pharmacology in drug development.